----
Current ValuationThe current P/E ratio is -5.29, below the reasonable range, cheaper than 81.23% of the time in the past 1 years, and the industry ranks 165/255, the industry Median -1.31.
-5.29xP/E
$2.87Stock price
$-0.54Earnings per share
-5.29xP/E
Stock price$2.87Earnings per share$-0.54
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -2.60x
- Typical range
- -5.26x–-1.67x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
0285684112
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
| Name/Symbol | |||
|---|---|---|---|
TAKUSTakeda Pharmaceutical Company | -53.89x | 148.12% | $56.27B |
BAYRYUSBayer | -24.13x | -- | $48.69B |
BAYZFUSBayer Aktiengesellschaft | -24.10x | -- | $48.62B |
VTRSUSViatris | -49.28x | 107.75% | $20.24B |
ELANUSElanco Animal Health | -56.52x | 129.36% | $11.25B |
AXSMUSAxsome Therap | -48.40x | 26.61% | $9.28B |
VREOFUSVIREO GROWTH INC | -132.19x | -- | $8.87B |
CURLFUSCuraleaf Holdings, Inc. | -143.59x | -- | $7.47B |
BLTEUSBelite Bio | -62.62x | 29.87% | $6.41B |
MANEUSVeraDermics | -47.62x | 97.44% | $4.97B |
DFTXUSDefinium Therapeutics | -13.76x | 53.61% | $4.87B |
EWTXUSEdgewise Therapeutics | -22.19x | 137.29% | $4.38B |
RGCUSRegencell Bioscience | -508.93x | -- | $3.59B |
AMLXUSAmylyx Pharmaceuticals | -22.93x | 1.76% | $3.49B |
ELVNUSEnliven Therapeutics | -31.45x | 6.39% | $3.33B |
TARSUSTarsus Pharmaceuticals | -70.30x | 205.82% | $3.27B |
MBXUSMBX Biosciences | -27.03x | 31.12% | $2.82B |
SUPNUSSupernus Pharma | -22.62x | 70.59% | $2.49B |
BHCUSBausch Health | -2.01x | 307.94% | $2.20B |
PHVSUSPharvaris BV | -10.79x | 9.52% | $2.14B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
